Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T with Bipolar Androgen Therapy in mCRPC
NCT06100705Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone cypionate, sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Yale University. Started Dec 2023; status: recruiting.
02
Drugs
testosterone cypionatesipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06100705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100705.